Abivax SA Sponsored ADR $ABVX Position Increased by Eversept Partners LP

Eversept Partners LP raised its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 54.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 657,834 shares of the company’s stock after purchasing an additional 231,335 shares during the quarter. Abivax accounts for approximately 4.5% of Eversept Partners LP’s portfolio, making the stock its 4th largest position. Eversept Partners LP owned about 0.83% of Abivax worth $88,712,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. purchased a new stake in Abivax in the third quarter valued at approximately $38,827,000. Persistent Asset Partners Ltd purchased a new stake in Abivax in the third quarter valued at approximately $815,000. Nan Fung Trinity HK Ltd. raised its position in Abivax by 11.8% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 113,365 shares of the company’s stock valued at $15,288,000 after purchasing an additional 12,000 shares during the period. Atika Capital Management LLC purchased a new stake in Abivax in the third quarter valued at approximately $5,858,000. Finally, Total Clarity Wealth Management Inc. purchased a new stake in Abivax in the fourth quarter valued at approximately $1,247,000. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Trading Up 2.7%

Abivax stock opened at $100.15 on Thursday. Abivax SA Sponsored ADR has a twelve month low of $5.69 and a twelve month high of $148.83. The stock’s fifty day simple moving average is $114.81 and its 200-day simple moving average is $118.49. The firm has a market capitalization of $7.99 billion, a P/E ratio of -19.22 and a beta of 0.69.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analysts’ expectations of $0.40 million. Sell-side analysts predict that Abivax SA Sponsored ADR will post -3.4 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on ABVX shares. Wedbush raised Abivax from an “underperform” rating to a “neutral” rating and cut their target price for the company from $110.00 to $90.00 in a research report on Tuesday, June 2nd. Citigroup reaffirmed an “outperform” rating on shares of Abivax in a research report on Tuesday, June 2nd. Wolfe Research set a $136.00 price objective on Abivax in a research report on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Finally, Barclays upped their price objective on Abivax from $142.00 to $148.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 24th. Twelve equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.08.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.